A Phase IIb, Randomized, Placebo-Controlled, Dose-Ranging Study of MK5442 in the Treatment of Postmenopausal Women With Osteoporosis.

Trial Profile

A Phase IIb, Randomized, Placebo-Controlled, Dose-Ranging Study of MK5442 in the Treatment of Postmenopausal Women With Osteoporosis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Encaleret (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Oct 2012 Results presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.
    • 15 Oct 2012 Primary endpoint 'Lumbar-spine-bone-mineral-density' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top